JP2022501389A5 - - Google Patents

Info

Publication number
JP2022501389A5
JP2022501389A5 JP2021516763A JP2021516763A JP2022501389A5 JP 2022501389 A5 JP2022501389 A5 JP 2022501389A5 JP 2021516763 A JP2021516763 A JP 2021516763A JP 2021516763 A JP2021516763 A JP 2021516763A JP 2022501389 A5 JP2022501389 A5 JP 2022501389A5
Authority
JP
Japan
Prior art keywords
sbcma
antibody
seq
monoclonal antibody
indicated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021516763A
Other languages
English (en)
Japanese (ja)
Other versions
JP7596260B2 (ja
JP2022501389A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/053433 external-priority patent/WO2020069303A1/en
Publication of JP2022501389A publication Critical patent/JP2022501389A/ja
Publication of JP2022501389A5 publication Critical patent/JP2022501389A5/ja
Priority to JP2024100215A priority Critical patent/JP2024147571A/ja
Application granted granted Critical
Publication of JP7596260B2 publication Critical patent/JP7596260B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021516763A 2018-09-28 2019-09-27 可溶性ｂｃｍａに対する抗体 Active JP7596260B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024100215A JP2024147571A (ja) 2018-09-28 2024-06-21 可溶性ｂｃｍａに対する抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862738997P 2018-09-28 2018-09-28
US62/738,997 2018-09-28
PCT/US2019/053433 WO2020069303A1 (en) 2018-09-28 2019-09-27 Antibodies against soluble bcma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024100215A Division JP2024147571A (ja) 2018-09-28 2024-06-21 可溶性ｂｃｍａに対する抗体

Publications (3)

Publication Number Publication Date
JP2022501389A JP2022501389A (ja) 2022-01-06
JP2022501389A5 true JP2022501389A5 (https=) 2022-10-04
JP7596260B2 JP7596260B2 (ja) 2024-12-09

Family

ID=68296657

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021516763A Active JP7596260B2 (ja) 2018-09-28 2019-09-27 可溶性ｂｃｍａに対する抗体
JP2024100215A Withdrawn JP2024147571A (ja) 2018-09-28 2024-06-21 可溶性ｂｃｍａに対する抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024100215A Withdrawn JP2024147571A (ja) 2018-09-28 2024-06-21 可溶性ｂｃｍａに対する抗体

Country Status (11)

Country Link
US (1) US11505614B2 (https=)
EP (1) EP3856781A1 (https=)
JP (2) JP7596260B2 (https=)
KR (1) KR20210068408A (https=)
CN (1) CN112703204B (https=)
AR (1) AR116548A1 (https=)
BR (1) BR112021005669A2 (https=)
MA (1) MA53732A (https=)
TW (1) TW202028239A (https=)
UY (1) UY38393A (https=)
WO (1) WO2020069303A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3819007T (lt) * 2019-11-11 2024-10-10 Amgen Research (Munich) Gmbh Dozavimo režimas, skirtas anti-bcma agentams
JP2025542567A (ja) * 2022-11-04 2025-12-26 ミンク セラピューティクス，インコーポレイティッド Ｂ細胞成熟抗原（ｂｃｍａ）キメラ抗原受容体インバリアントナチュラルキラーｔ細胞及びその用途
WO2024168192A1 (en) * 2023-02-10 2024-08-15 Celgene Corporation Assessment of bcma in biological samples
CN119529089B (zh) * 2023-08-28 2025-11-18 菲鹏生物股份有限公司 一种抗生长刺激表达基因2蛋白的抗体及其应用

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1985A (en) 1841-02-18 Charles m
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
ES2142801T3 (es) 1991-03-11 2000-05-01 Univ Georgia Res Found Clonacion y expresion de luciferasa de renilla.
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US7381803B1 (en) 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
EP0759170B1 (en) 1993-09-10 2008-07-09 The Trustees Of Columbia University In The City Of New York Uses of green fluorescent protein
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
US5925558A (en) 1996-07-16 1999-07-20 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
IL129767A0 (en) 1996-12-12 2000-02-29 Prolume Ltd Apparatus and method for detecting and identifying infectious agents
JP2002507410A (ja) 1998-03-27 2002-03-12 プロルーム・リミテッド ルシフェラーゼ、蛍光タンパク質、ルシフェラーゼおよび蛍光タンパク質をコードする核酸および、診断、高処理スクリーニングおよび新規アイテムにおけるその使用
US7112324B1 (en) 1998-04-21 2006-09-26 Micromet Ag CD 19×CD3 specific polypeptides and uses thereof
GB9815909D0 (en) 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
AU5728999A (en) 1998-07-28 2000-02-21 Micromet Ag Heterominibodies
MXPA06004035A (es) 2003-10-16 2006-08-31 Micromet Ag Aglutinantes cd3 de-inmunizados multi-especificos.
CA2569509C (en) 2004-06-03 2014-08-12 Novimmune S.A. Anti-cd3 antibodies and methods of use thereof
RS53008B2 (sr) 2007-04-03 2022-12-30 Amgen Res Munich Gmbh Interspecijski specifičan cd3-epsilon vezujući domen
EP2352765B1 (en) 2008-10-01 2018-01-03 Amgen Research (Munich) GmbH Cross-species-specific single domain bispecific single chain antibody
KR101972446B1 (ko) 2011-05-27 2019-04-25 글락소 그룹 리미티드 Ｂｃｍａ（ｃｄ２６９／ｔｎｆｒｓｆ１７）­결합 단백질
NO2748201T3 (https=) 2011-08-23 2018-05-12
WO2013026837A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
TWI679212B (zh) * 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
US11634502B2 (en) 2013-03-15 2023-04-25 Amgen Inc. Heterodimeric bispecific antibodies
US20140308285A1 (en) 2013-03-15 2014-10-16 Amgen Inc. Heterodimeric bispecific antibodies
AR095374A1 (es) * 2013-03-15 2015-10-14 Amgen Res Munich Gmbh Moléculas de unión para bcma y cd3
US20160257748A1 (en) 2013-09-25 2016-09-08 Amgen Inc. V-c-fc-v-c antibody
EP3029068A1 (en) * 2014-12-03 2016-06-08 EngMab AG Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
CN108473575B (zh) * 2015-11-13 2022-04-19 美国卫生和人力服务部 抗-bcma多肽和蛋白质
ES2898329T3 (es) * 2016-01-12 2022-03-07 Oncotracker Inc Métodos mejorados para supervisar el estado inmunitario de un sujeto
IL313507A (en) 2016-02-03 2024-08-01 Amgen Res Munich Gmbh Constructs of bispecific antibodies to BCMA and CD3 that bind to T cells, preparations containing the same and uses thereof

Similar Documents

Publication Publication Date Title
JP2023002583A (ja) Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測
EP3519824B1 (en) Improved methods of assessing uch-l1 in patient samples
CN107001455B (zh) 利用hnl的诊断方法
AU2018272054B2 (en) Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
JP2022501389A5 (https=)
AU2018378084A1 (en) Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of GFAP and UCH-L1
AU2018378971A1 (en) Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (TBI), using glial fibrillary acidic protein (GFAP) and/or ubiquitin carboxy-terminal hydrolase l1 (UCH-L1)
JP2020516888A (ja) 早期バイオマーカーを使用する、ヒト対象における外傷性脳損傷の、超急性の診断及び決定の一助となるための方法
WO2015013388A2 (en) Anti-galectin-1 monoclonal antibodies and fragments thereof
JP2022031643A (ja) Ｉｌ２３アンタゴニストに対する臨床応答の予測因子としてのｃｃｌ２０
US12055552B2 (en) Method for diagnosis based on circulating extracellular vesicles
JP2020526745A (ja) 血液中のユビキチンカルボキシ末端ヒドロラーゼｌ１レベルを測定するための、改善された方法
EP4396587A1 (en) Methods and systems of diagnosing brain injury
EP3602069A1 (en) Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
CN118715440A (zh) 诊断脑损伤的方法和系统
US20250264468A1 (en) Compositions and methods for the detection of coccidioidal chitinase-1
Fichtner et al. Self-antigen driven affinity maturation is required for pathogenic monovalent IgG4 autoantibody development
WO2025037271A1 (en) Plasma assay for detecting cns-derived tau peptides
HK40123156A (en) Improved methods of assessing uch-l1 status in patient samples
WO2024226971A1 (en) Improved assays, cartridges, and kits for detection of biomarkers, including brain injury biomarkers
WO2022245920A9 (en) Methods of evaluating brain injury in a pediatric subject
EA045805B1 (ru) Анализы для выявления нейродегенеративных заболеваний
HK1237281B (zh) 可溶性人st-2抗体和分析法